3-(4-哌啶基)-1-丁醇 | 89151-40-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 3-(4-哌啶基)-1-丁醇
• 英文名称: 4-(1-hydroxybut-3-yl)piperidine
• 英文别名: 3-(4-Piperidyl)-1-butanol；3-piperidin-4-ylbutan-1-ol
• CAS: 89151-40-6
• 化学式: C₉H₁₉NO
• 分子量: 157.256
• InChiKey: QPVNMDQHBZKJGM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  32.3
• 氢给体数：
  2
• 氢受体数：
  2

文献信息

• PIPERIDINE GPCR AGONISTS
  申请人：Bertram Lisa Sarah

  公开号：US20100022591A1

  公开（公告）日：2010-01-28

  Compounds of formula (I): or pharmaceutically acceptable salts thereof, are GPCR agonists and are useful as for the treatment of obesity and diabetes.

  式(I)的化合物或其药学上可接受的盐，是GPCR激动剂，可用于治疗肥胖症和糖尿病。
• Piperidine GPCR Agonists
  申请人：Fyfe Matthew Colin Thor

  公开号：US20100048631A1

  公开（公告）日：2010-02-25

  Compounds of formula (I): or pharmaceutically acceptable salts thereof, are GPCR agonists and are useful as for the treatment of obesity and diabetes.

  化合物公式（I）或其药学上可接受的盐是GPCR激动剂，可用于治疗肥胖症和糖尿病。
• Heterocyclic GPCR Agonists
  申请人：Bertram Lisa Sarah

  公开号：US20110178054A1

  公开（公告）日：2011-07-21

  Compounds of formula (I): or pharmaceutically acceptable salts thereof, are GPCR (GPR119) agonists and are useful as for the treatment of diabetes and obesity.

  式(I)的化合物或其药学上可接受的盐是GPCR（GPR119）激动剂，可用于治疗糖尿病和肥胖症。
• Compounds for the Treatment of Metabolic Disorders
  申请人：Barba Oscar

  公开号：US20120059014A1

  公开（公告）日：2012-03-08

  The present invention is directed to therapeutic compounds of the following formula (I) which have activity as agonists of GPR119 and are useful for the treatment of metabolic disorders including type II diabetes.

  本发明涉及以下式(I)的治疗化合物，其具有作为GPR119激动剂的活性，可用于治疗代谢紊乱，包括II型糖尿病。
• COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS
  申请人：Barba Oscar

  公开号：US20100286112A1

  公开（公告）日：2010-11-11

  The present invention is directed to therapeutic compounds which have dual activity as agonists of GPR119 and inhibitors of DPP-IV and are useful for the treatment of metabolic disorders including type II diabetes.

  本发明涉及治疗化合物，其具有作为GPR119激动剂和DPP-IV抑制剂的双重活性，并可用于治疗代谢性疾病，包括II型糖尿病。